|
See related Zemplar inj[亞培腎骨樂 注射劑 "亞培"] information |
|
|
|
製造商 |
Abbott |
|
代理/經銷商 |
Abbott |
|
成份 |
Paricalcitol |
|
適應症 |
Prevention & treatment of secondary hyperparathyroidism associated with chronic renal insufficiency ([CKD] stage 5). |
|
用量 |
Recommended initial dose: 0.04-0.1 mcg/kg (2.8-7 mcg) administered as a bolus IV inj every other day or less frequently. Max initial dose: 40 mcg. The dose may be increased if necessary by 2-4 mcg at intervals of 2-4 weeks. |
|
美國食品藥物管理局之懷孕等級 |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
禁忌 |
Patients with evidence of vit D toxicity & hypercalcemia. |
|
注意事項 |
Monitor serum Ca & phosphorus levels closely during dose adjustment; also monitor serum or plasma parathyroid hormone (PTH) levels. Pregnancy, lactation. Patients <18 years. |
|
不良反應 |
Chills, discomfort, fever, flu, sepsis; palpitation; dry mouth, GI bleeding, nausea, vomiting; edema; lightheadedness, pneumonia. Rarely, hypersensitivity reactions, urticaria, facial edema, metallic taste, skin rash, itch.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
Strong inhibitors of CYP450 3A (e.g. ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole); digitalis.
View more drug interactions with Zemplar[亞培腎骨樂] |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Zemplar 注射劑 |
|
Zemplar 5 mcg/1 mL x 1 mL |
|
|
|
Manufacturer: |
Abbott |
|
Distributor: |
Abbott |
|
|
|
|
